856 | MARSUN, A PHASE III, MULTICENTER, OPEN LABEL, RANDOMIZED STUDY INVESTIGATING MOSUNETUZUMAB‐LENALIDOMIDE VERSUS INVESTIGATOR CHOICES IN R/R MARGINAL ZONE LYMPHOMAS

Documenti analoghi

• 251 | HIGH COMPLETE RESPONSE RATES AND DIFFERENTIAL TOXICITY OF MOSUNETUZUMAB AND LENALIDOMIDE IN PREVIOUSLY UNTREATED FOLLICULAR AND MARGINAL ZONE LYMPHOMA
  di: A. J. Olszewski, et al.
  Pubblicazione: (2025)
• 229 | SAFETY AND EFFICACY OF MOSUNETUZUMAB SUBCUTANEOUS MAINTENANCE FOLLOWING MOSUNETUZUMAB PLUS LENALIDOMIDE INDUCTION THERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
  di: T. A. Eyre, et al.
  Pubblicazione: (2025)
• 259 | IELSG49: A PHASE II TRIAL OF ACALABRUTINIB IN COMBINATION WITH TAFASITAMAB IN PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMAS
  di: M. C. Pirosa, et al.
  Pubblicazione: (2025)
• 52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY
  di: C. Thieblemont, et al.
  Pubblicazione: (2025)
• 92 | EO2463 (EO) PEPTIDE IMMUNOTHERAPY IN COMBINATION WITH LENALIDOMIDE (L) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH FOLLICULAR (FL) AND MARGINAL ZONE LYMPHOMA (MZL)
  di: J. C. Villasboas, et al.
  Pubblicazione: (2025)